- Home
- SLS vs ANIK Comparison
SLS vs ANIK Comparison
Compare SLS & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | ANIK |
|---|---|---|
| Founded | 2012 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.0M | 142.5M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | SLS | ANIK |
|---|---|---|
| Price | $2.06 | $9.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 4.4M | 182.3K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $112,806,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.55 |
| 52 Week Low | $0.77 | $7.87 |
| 52 Week High | $2.48 | $18.37 |
Technical Indicators
Market Signals| Indicator | SLS | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 47.89 |
| Support Level | $1.39 | $9.48 |
| Resistance Level | $2.00 | $9.75 |
| Average True Range (ATR) | 0.14 | 0.26 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 89.73 | 24.05 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.